Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

46.92
-0.0900-0.19%
Post-market: 47.050.1300+0.28%16:57 EDT
Volume:7.02M
Turnover:330.10M
Market Cap:95.49B
PE:17.57
High:47.27
Open:47.21
Low:46.70
Close:47.01
Loading ...

Bristol Myers Squibb Announces Dividend

THOMSON REUTERS
·
18 Jun

Bristol-Myers Squibb Files Initial Statement of Beneficial Ownership for Hiroshi Chris Shibutani, EVP and Chief Strategy Officer

Reuters
·
17 Jun

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
17 Jun

Bristol-Myers Squibb Says Breyanzi Shows 'Lasting' Response in Marginal Zone Lymphoma Trial

MT Newswires Live
·
16 Jun

BRIEF-Bristol Myers Squibb Reports Strong Breyanzi Results in MZL Cohort of TRANSCEND FL Trial

Reuters
·
16 Jun

Bristol Myers Squibb to Present Pivotal Data at International Conference on Malignant Lymphoma

Reuters
·
16 Jun

Bristol-Myers Squibb Co - 95.5% of Mzl Patients Treated With Liso-Cel Achieved Response

THOMSON REUTERS
·
16 Jun

Bristol Myers Squibb Presents First Data From the Marginal Zone Lymphoma Cohort of the Transcend Fl Trial Demonstrating Deep and Durable Responses With Breyanzi (Lisocabtagene Maraleucel)

THOMSON REUTERS
·
16 Jun

2 Beaten-Down Dividend Stocks to Buy Right Now

Motley Fool
·
16 Jun

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
14 Jun

Bloomsbury Publishing Releases 2025 Annual Financial Report

TIPRANKS
·
14 Jun

Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
13 Jun

Cantor Fitzgerald Remains a Hold on Bristol-Myers Squibb (BMY)

TIPRANKS
·
12 Jun

Bristol Myers presents data on protein degradation platform

TIPRANKS
·
12 Jun

Bristol Myers Squibb Unveils Promising Clinical Data on Innovative Cancer Therapies at EHA 2025 Annual Congress

Reuters
·
12 Jun

Bristol Myers Squibb to Announce Second Quarter 2025 Financial Results

Reuters
·
12 Jun

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

THOMSON REUTERS
·
12 Jun

Bristol-Myers Squibb Says Co Strongly Believes That Cancer Drug Opdivo Qvantig Should Be Excluded From Medicare Drug Price Negotiation - Goldman Sachs Conf

THOMSON REUTERS
·
11 Jun

Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis

Reuters
·
11 Jun

Bristol Myers Squibb Presents Late-Breaking Data From Pivotal Phase 3 Poetyk Psa-1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared With Placebo in Adults With Psoriatic Arthritis

THOMSON REUTERS
·
11 Jun